Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to 0.43.

  • Arcutis Biotherapeutics' Equity Ratio rose 1897.02% to 0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43, marking a year-over-year increase of 1897.02%. This contributed to the annual value of 0.45 for FY2024, which is 7384.54% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Equity Ratio of 0.43 as of Q3 2025, which was up 1897.02% from 0.39 recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Equity Ratio peaked at 0.96 during Q2 2021, and registered a low of 0.16 during Q3 2023.
  • Its 5-year average for Equity Ratio is 0.52, with a median of 0.45 in 2024.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 7002.87% in 2023, then surged by 12459.72% in 2024.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Equity Ratio stood at 0.73 in 2021, then tumbled by 36.04% to 0.47 in 2022, then plummeted by 44.32% to 0.26 in 2023, then skyrocketed by 73.85% to 0.45 in 2024, then decreased by 5.64% to 0.43 in 2025.
  • Its Equity Ratio stands at 0.43 for Q3 2025, versus 0.39 for Q2 2025 and 0.41 for Q1 2025.